School of Medicine’s biochemistry department team, in partnership with Q2 Pharma, to develop antivirulence agents that disarm bacteria of deadly toxins

About the Author

Q2 Pharma is developing small-molecule antivirulence agents against bacterial infections.

Leave a Reply